Bexxar Corixa/GlaxoSmithKline

Current Opinion in Investigational Drugs

Volumn 3, Issue 1, 2002, Pages 165-170

  Cheson, Bruce ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIGEN MONOCLONAL ANTIBODY B1; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; MONOCLONAL ANTIBODY; PREDNISONE; RADIOPHARMACEUTICAL AGENT; RITUXIMAB; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; VINCRISTINE; IODINE 131 ANTI B1 ANTIBODY; IODINE-131 ANTI-B1 ANTIBODY;

ACUTE LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; DRUG APPROVAL; DRUG COST; DRUG FEVER; DRUG METABOLISM; DRUG RESPONSE; DRUG SYNTHESIS; HEADACHE; HUMAN; HYPOTHYROIDISM; ISOTOPE LABELING; MAXIMUM TOLERATED DOSE; MYELODYSPLASIA; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; METHODOLOGY; PHARMACEUTICS; STATISTICS;

ANIMAL; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; HUMAN; LYMPHOMA, NON-HODGKIN; TECHNOLOGY, PHARMACEUTICAL; ANIMALS; HUMANS;

EID: 0035985650     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Radioimmunotherapy of B-cell lymphoma with [131-I]anti-B1 (anti-CD20) antibody
2. Phase II trial of 131-I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas
3. Follicular lymphoma: Prognostic factors for response and survival
4. Coulter Pharmaceutical, Inc starts pivotal phase II/III trial; Trial of radioimmunotherapeutic in non-Hodgkin's lymphoma
5. Iodine-131-Anti-B1 radioimmunotherapy for B-cell lymphoma
6. Coulter Pharmaceutical begins outpatient treatment with Bexxar - Manufacturing Process Centralized
7. I-131 anti-B1 antibody for previously untreated follicular lymphoma (FL): Clinical and molecular remissions
8. Independent review of response to iodine-131 antibody in low-grade or transformed low-grade non-Hodgkin's lymphoma
9. Coulter Pharmaceutical initiates expanded access program
10. Coulter Pharmaceutical and SmithKline Beecham form development and commercialization alliance for I-131 anti-B1 antibody
11. Coulter Pharmaceutical
12. Rituximab chimeric anti-CD20 monoclonal antibody therapy of relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
13. Coulter Pharmaceutical and SmithKline Beecham announce the submission of a Biologics License Application for Bexxar to FDA
14. SmithKline Beecham reports earnings per share increase of 16% for second quarter 1999, 15% excluding currency
15. Coulter Pharmaceutical and SmithKline Beecham announce priority review status for Bexxar
16. 131 tositumomab for patients with small lymphocytic lymphoma (SLL): Overall clinical trial experience
17. Iodine I 131 tositumomab for patients with follicular non-Hodgkin'd lymphoma (NHL): Overall clinical trial experience by histology
18. Extent of disease impacts the effective half-life of iodine I 131 tositumomab in non-Hodgkin's lymphoma (NHL)
19. Fludarabine monophosphate followed by iodine I 131 tositumomab for untreated low-grade and follicular non-Hodgkin's lymphoma (NHL)
20. Bexxar (tositumomab, iodine I 131 tositumomab) can be safely administered in relapsed low-grade or transformed low-grade non-Hodgkin's lymphoma patients after prior treatment with rituximab: Initial experience from the expanded access study
21. Masked independent randomized radiology and oncology (MIRROR) review panel assessment of response in phase III trial of iodine I 131 tositumomab
22. Iodine I 131 tositumomab therapy for previously untreated follicular lymphoma (FL)
23. Corixa and Coulter merge to create a comprehensive immunotherapy company
24. Development of HAMA after Bexxar therapy does not preclude treatment with rituximab
25. Iodine-131 tositumomab for non-Hodgkin's lymphoma (NHL) patients who progressed after treatment with ritumixab: Results of multicenter phase II study
26. Iodine I 131 tositumomab for patients with low-grade or transformed low-grade NHL: Complete response data
27. Corixa and Coulter complete merger to form comprehensive immunotherapy company
28. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas
29. Merrill Lynch Global Pharmaceutical Investor Conference - September 25, 2001
30. Some like it hot!
31. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
32. Characterization of the apoptotic process initiated by ligation of CD20 by the mouse monoclonal antibody anti-B1 in the Burkitt's lymphoma cell line Ramos
33. Characterization of a human B-lymphocyte-specific antigen
34. Radioimmunotherapy with iodine (131) tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience
35. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas
36. Interim efficacy results of Bexxar in a large multicenter expanded access study
37. Efficacy and safety of Bexxar in the expanded access study: Interim report from two institutions
38. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts
39. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue
40. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas
41. Synergistic cytotoxicity of iodine-131-anti-CD20 antibodies and chemotherapy for treatment of B-cell lymphomas
42. A predictive model for aggressive non-non-Hodgkin's lymphoma
43. Monoclonal antibodies in the treatment of hematologic malignancies: Future directions
44. Multicenter, phase III study of iodine-131 tositumomab (anti-B1 antibody) for chemotherapy-refractory low-grade or transformed low-grade non-Hodgkin's lymphoma
45. S0016 - Phase III trial of CHOP vs. CHOP + Rituximab vs. CHOP + I-131-labeled monoclonal anti-B1 antibody (tositumomab) for treatment of newly diagnosed follicular non-Hodgkin's lymphoma
46. Tolerance of treatment subsequent to frontline Bexxar(TM) (tositumomab and iodine I 131 tositumomab) in patients (Pts) with follicular lymphoma
47. 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts
48. Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody